Abstract
Inclusion bodies (50-500 nm in diameter) produced in recombinant bacteria can be engineered to contain functional proteins with therapeutic potential. Upon exposure, these protein particles are efficiently internalized by mammalian cells and promote recovery from diverse stresses. Being fully biocompatible, inclusion bodies are a novel platform, as tailored nanopills, for sustained drug release in advanced cell therapies.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Catalase / administration & dosage
-
Catalase / therapeutic use
-
Cell Line
-
Cell Membrane Permeability
-
Delayed-Action Preparations / metabolism*
-
Escherichia coli / metabolism*
-
Green Fluorescent Proteins / administration & dosage
-
HSP70 Heat-Shock Proteins / administration & dosage
-
HSP70 Heat-Shock Proteins / therapeutic use
-
HeLa Cells
-
Humans
-
Inclusion Bodies / metabolism*
-
Leukemia Inhibitory Factor / administration & dosage
-
Leukemia Inhibitory Factor / therapeutic use
-
Mice
-
Recombinant Proteins / administration & dosage*
-
Recombinant Proteins / therapeutic use
-
Tetrahydrofolate Dehydrogenase / administration & dosage
-
Tetrahydrofolate Dehydrogenase / therapeutic use
Substances
-
Delayed-Action Preparations
-
HSP70 Heat-Shock Proteins
-
Leukemia Inhibitory Factor
-
Recombinant Proteins
-
Green Fluorescent Proteins
-
Catalase
-
Tetrahydrofolate Dehydrogenase